NASDAQ:SLP - Simulations Plus Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$17.45 -0.60 (-3.32 %)
(As of 07/16/2018 02:25 PM ET)
Previous Close$17.85
Today's Range$17.40 - $18.15
52-Week Range$13.37 - $23.95
Volume5,522 shs
Average Volume127,899 shs
Market Capitalization$313.44 million
P/E Ratio53.09
Dividend Yield1.33%
Beta-0.6
Simulations Plus logoSimulations Plus, Inc. develops drug discovery and development software for mechanistic modeling and simulation worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), and pharmacodynamics of drugs administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments, which measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments. It also provides PKPlus, a standalone program that provides the functionality needed by pharmaceutical industry scientists to perform the analyses and generate the outputs needed to satisfy regulatory agency requirements for NCA and compartmental PK modelling; ADMET Predictor, a chemistry-based computer program, which takes molecular structures as inputs and predicts their properties; and MedChem Designer, a molecule drawing program or sketcher that integrates with MedChem Studio and ADMET Predictor. In addition, it offers MedChem Studio, a software tool for data mining and designing new molecules; KIWI, a cloud-based Web application, which organizes, processes, maintains, and communicates the volume of data and results generated by pharmacologists and scientists over the duration of a drug development program; DILIsym, a quantitative systems pharmacology software; and DILIsym, a software that is used to investigate the likelihood that a known drug molecule would cause injury to the liver. Further, the company provides consulting services ranging from early drug discovery through preclinical and clinical trial data analysis, and for submissions to regulatory agencies; and population modeling and simulation contract research services for the pharmaceutical and biotechnology industries. Additionally, it offers its pharmaceutical/chemistry software to pharmaceutical, biotechnology, agrochemical, and food companies. Simulations Plus, Inc. was founded in 1996 and is headquartered in Lancaster, California.

Receive SLP News and Ratings via Email

Sign-up to receive the latest news and ratings for SLP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Computer integrated systems design
Sub-IndustryN/A
SectorComputer and Technology
SymbolNASDAQ:SLP
CUSIPN/A
Phone661-723-7723

Debt

Debt-to-Equity RatioN/A
Current Ratio3.33
Quick Ratio2.78

Price-To-Earnings

Trailing P/E Ratio53.09
Forward P/E Ratio43.63
P/E GrowthN/A

Sales & Book Value

Annual Sales$24.14 million
Price / Sales12.55
Cash Flow$0.4493 per share
Price / Cash38.84
Book Value$1.79 per share
Price / Book9.75

Profitability

EPS (Most Recent Fiscal Year)$0.34
Net Income$5.78 million
Net Margins29.88%
Return on Equity25.65%
Return on Assets17.87%

Miscellaneous

Employees86
Outstanding Shares17,360,000
Market Cap$313.44

The Truth About Cryptocurrencies

Simulations Plus (NASDAQ:SLP) Frequently Asked Questions

What is Simulations Plus' stock symbol?

Simulations Plus trades on the NASDAQ under the ticker symbol "SLP."

How often does Simulations Plus pay dividends? What is the dividend yield for Simulations Plus?

Simulations Plus declared a quarterly dividend on Wednesday, July 11th. Investors of record on Thursday, July 26th will be paid a dividend of $0.06 per share on Thursday, August 2nd. This represents a $0.24 annualized dividend and a yield of 1.38%. The ex-dividend date is Wednesday, July 25th. View Simulations Plus' Dividend History.

How were Simulations Plus' earnings last quarter?

Simulations Plus, Inc. (NASDAQ:SLP) announced its quarterly earnings results on Tuesday, July, 10th. The technology company reported $0.13 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.12 by $0.01. The technology company had revenue of $8.55 million for the quarter, compared to analysts' expectations of $7.86 million. Simulations Plus had a return on equity of 25.65% and a net margin of 29.88%. View Simulations Plus' Earnings History.

What is the consensus analysts' recommendation for Simulations Plus?

0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Simulations Plus in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."

Who are some of Simulations Plus' key competitors?

Who are Simulations Plus' key executives?

Simulations Plus' management team includes the folowing people:
  • Mr. Walter S. Woltosz, Chairman & CEO (Age 73)
  • Mr. John R. Kneisel, Chief Financial Officer (Age 60)
  • Ms. Virginia E. Woltosz, Sec. & Treasurer (Age 67)
  • Mr. John Anthony DiBella, Pres of the Lancaster Division (Age 38)
  • Dr. Thaddeus Henry Grasela Jr., PharmD, Ph.D., Pres of Cognigen Corp. & Director (Age 64)

Has Simulations Plus been receiving favorable news coverage?

Headlines about SLP stock have trended positive recently, according to Accern Sentiment. Accern scores the sentiment of news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Simulations Plus earned a media sentiment score of 0.43 on Accern's scale. They also assigned headlines about the technology company an impact score of 47.48 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future.

Who are Simulations Plus' major shareholders?

Simulations Plus' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Campbell & CO Investment Adviser LLC (0.13%) and Bank of Montreal Can (0.05%). Company insiders that own Simulations Plus stock include Argenio David Z D, John Robert Kneisel, Thaddeus Henry Grasela Jr, Virginia E Woltosz and Walter S Woltosz. View Institutional Ownership Trends for Simulations Plus.

Which major investors are buying Simulations Plus stock?

SLP stock was bought by a variety of institutional investors in the last quarter, including Campbell & CO Investment Adviser LLC and Bank of Montreal Can. View Insider Buying and Selling for Simulations Plus.

How do I buy shares of Simulations Plus?

Shares of SLP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Simulations Plus' stock price today?

One share of SLP stock can currently be purchased for approximately $17.40.

How big of a company is Simulations Plus?

Simulations Plus has a market capitalization of $313.44 million and generates $24.14 million in revenue each year. The technology company earns $5.78 million in net income (profit) each year or $0.34 on an earnings per share basis. Simulations Plus employs 86 workers across the globe.

How can I contact Simulations Plus?

Simulations Plus' mailing address is 42505 10TH STREET WEST, LANCASTER CA, 93534. The technology company can be reached via phone at 661-723-7723 or via email at [email protected]


MarketBeat Community Rating for Simulations Plus (NASDAQ SLP)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  130 (Vote Outperform)
Underperform Votes:  165 (Vote Underperform)
Total Votes:  295
MarketBeat's community ratings are surveys of what our community members think about Simulations Plus and other stocks. Vote "Outperform" if you believe SLP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SLP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.